Methods and pharmaceuticals for treatment of viral infections of the eye

Abstract

Viral infections of the eye, and particularly viral infections in the Herpesviridae and Adenoviridae families, can be treated by administration of a pharmaceutical made up of an enzymatically active ribonuclease and a vehicle. Advantageously, the enzymatically active ribonuclease is ranpirnase, the '805 variant, rAmphinase 2, and Amphinase 2, and the vehicle is an aqueous solution.

1 . A method of treating a herpesviral infection of the eye, comprising the step of administering to the eye a therapeutically effective dose of a ribonuclease that is a member of the ribonuclease A superfamily. 
     
     
         2 . The method of  claim 1 , wherein the eye is a human eye and the ribonuclease is selected from a group consisting of
 a. ranpirnase;   b. the '805 variant;   c. Amphinase 2; and   d. rAmphinase 2.   
     
     
         3 . The method of  claim 1 , wherein the ribonuclease is non-irritating to the eye as determined using
 a. the Globally Harmonized System of Classification Evaluation Criteria and   b. the European Economic Community Ocular Evaluation Criteria.   
     
     
         4 . The method of  claim 1 , wherein the eye is a human eye and the ribonuclease is functionally equivalent to a ribonuclease selected from a group consisting of:
 a. ranpirnase;   b. the '805 variant;   c. Amphinase 2; and   d. rAmphinase 2.   
     
     
         5 . A method for treating a herpesviral infection of the human eye, the method comprising administering an ophthalmic composition to the eye, the composition comprising:
 a. a therapeutically effective dose of a ribonuclease that is a member of the ribonuclease A superfamily and that is non-irritating to the eye as determined using
 i. the Globally Harmonized System of Classification Evaluation Criteria and 
 ii. the European Economic Community Ocular Evaluation Criteria; and 
   b. a vehicle.   
     
     
         6 . The method of  claim 5 , wherein the ribonuclease is selected from a group consisting of:
 a. ranpirnase;   b. the '805 variant;   c. Amphinase 2; and   d. rAmphinase 2.   
     
     
         7 . The method of  claim 5 , wherein the vehicle is an aqueous solution. 
     
     
         8 . The method of  claim 5 , wherein the ribonuclease is the functional equivalent of a ribonuclease selected from a group consisting of
 a. ranpirnase;   b. the '805 variant;   c. Amphinase 2; and   d. rAmphinase 2.   
     
     
         9 . A method of treating a herpesviral infection of an eye, the method comprising the step of topically administering to the eye a therapeutically effective amount of a ranpirnase. 
     
     
         10 . The method according to  claim 9 , wherein the ranpirnase is a recombinant ranpirnase. 
     
     
         11 . The method according to  claim 9 , wherein the ranpirnase is SEQ ID NO: 1 or SEQ ID NO: 2. 
     
     
         12 . The method according to  claim 9 , wherein the herpesviral infection is the cause of chorioretinitis, viral keratitis, viral conjunctivitis, or cytomegalovirus retinitis. 
     
     
         13 . The method according to  claim 9 , wherein the herpesviral infection is caused by an type I Herpes simplex virus, human cytomegalovirus, or Herpes zoster virus. 
     
     
         14 . The method according to  claim 9 , wherein the ranpirnase is formulated as an ophthalmic pharmaceutical composition. 
     
     
         15 . The method according to  claim 14 , wherein the ophthalmic pharmaceutical composition is a solution, a suspension, a nanosuspension, an emulsion, a microemulsion, a nanoemulsion, an ointment, a gel, a hydrogel, liposomes, niosomes, nanoparticles, or dendrimers. 
     
     
         16 . The method according to  claim 14 , wherein the ophthalmic pharmaceutical composition further comprises a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient. 
     
     
         17 . The method according to  claim 9 , wherein the ranpirnase is administered as eye drops. 
     
     
         18 . The method according to  claim 9 , wherein the eye is a human eye. 
     
     
         19 . A pharmaceutical composition comprising:
 a. a therapeutically effective dose of a ribonuclease that is a member of the ribonuclease A superfamily and that is non-irritating to an eye as determined using
 i. the Globally Harmonized System of Classification Evaluation Criteria and 
 ii. the European Economic Community Ocular Evaluation Criteria; and 
   b. a vehicle.   
     
     
         20 . The pharmaceutical composition of  claim 19 , wherein the ribonuclease is selected from a group consisting of:
 a. ranpirnase;   b. the '805 variant;   c. Amphinase 2; and   d. rAmphinase 2.   
     
     
         21 . The pharmaceutical composition of  claim 19 , wherein the ribonuclease is the functional equivalent of a ribonuclease selected from a group consisting of
 a. ranpirnase;   b. the '805 variant;   c. Amphinase 2; and   d. rAmphinase 2.   
     
     
         22 . The pharmaceutical composition of  claim 19 , wherein the ribonuclease is ranpirnase present in an amount of 0.1%. 
     
     
         23 . The pharmaceutical composition of  claim 19 , formulated for topical administration to the eye. 
     
     
         24 . The pharmaceutical composition of  claim 23 , wherein the composition is formulated as a solution, a suspension, a nanosuspension, an emulsion, a microemulsion, a nanoemulsion, an ointment, a gel, a hydrogel, liposomes, niosomes, nanoparticles, or dendrimers. 
     
     
         25 . The pharmaceutical composition of  claim 19 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient.